The latest price target for AN2 Therapeutics (NASDAQ:ANTX) was reported by JMP Securities on August 9, 2024. The analyst firm set a price target for $3.00 expecting ANTX to rise to within 12 months (a possible 180.37% upside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for AN2 Therapeutics (NASDAQ:ANTX) was provided by JMP Securities, and AN2 Therapeutics maintained their market outperform rating.

The last upgrade for AN2 Therapeutics Inc happened on July 3, 2024 when Leerink Partners raised their price target to N/A. Leerink Partners previously had a market perform for AN2 Therapeutics Inc.

The last downgrade for AN2 Therapeutics Inc happened on February 13, 2024 when Leerink Partners changed their price target from $23 to $7 for AN2 Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AN2 Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AN2 Therapeutics was filed on August 9, 2024 so you should expect the next rating to be made available sometime around August 9, 2025.

While ratings are subjective and will change, the latest AN2 Therapeutics (ANTX) rating was a maintained with a price target of $6.00 to $3.00. The current price AN2 Therapeutics (ANTX) is trading at is $1.07, which is out of the analyst’s predicted range.